Home / Health / Melanoma Pioneer Treated Own Cancer: Dr. Scolyer Dies at 59
Melanoma Pioneer Treated Own Cancer: Dr. Scolyer Dies at 59
27 Jun
Summary
- Renowned pathologist Dr. Richard Scolyer died June 7 in Sydney at 59.
- He bravely documented his glioblastoma treatment, living past the median survival.
- His work advanced melanoma survival rates from under 5% to over 50%.
Dr. Richard Scolyer, a distinguished Australian pathologist whose research significantly advanced melanoma treatment, passed away on June 7 in Sydney at the age of 59. His work, particularly on melanoma which is Australia's national cancer due to high prevalence from sun exposure, led to a dramatic increase in survival rates.
In 2023, Dr. Scolyer was diagnosed with advanced glioblastoma, a severe brain cancer. He openly chronicled his experimental immunotherapy treatment, exceeding the typical survival timeframe. This personal journey illuminated his own research and inspired widespread public and governmental support.
The Australian government announced a $5.9 million contribution in 2025 to establish the Richard Scolyer Chair in Brain Research. This initiative aims to further cancer research and honor his contributions.
Dr. Scolyer's research at the Melanoma Institute Australia focused on mapping the melanoma genome and understanding how the cancer spreads, especially to the brain. His findings helped predict patient outcomes more effectively and informed treatment strategies.
In 2024, Dr. Scolyer and his colleague Dr. Georgina Long were jointly named Australian of the Year for their work that raised the five-year survival rate for advanced melanoma from less than 5 percent to over 50 percent.
He was born in Launceston, Tasmania, on December 16, 1966. His early life experiences, including his mother's strokes and his father's skin graft for a suspected melanoma, may have influenced his career path.
Dr. Scolyer's treatment for glioblastoma involved a combination of immunotherapy drugs, surgery, radiation, and a personalized cancer vaccine, mirroring successful protocols for advanced melanoma patients. Some of the drugs used in his treatment are now part of an ongoing clinical trial in the United States and Australia for newly diagnosed glioblastoma patients.
His legacy extends beyond his scientific achievements; he is remembered for his courage, determination, and grace in facing his illness, inspiring ongoing research and awareness for glioblastoma patients.
